MannKind Corporation’s (NASDAQ:MNKD) shares were down more than 7% following the release of briefing documents ahead of an FDA advisory panel meeting where the company’s diabetes candidate, Afrezza (inhaled insulin) will be reviewed. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee meeting is scheduled for Apr 1. MannKind Corporation (NASDAQ:MNKD) shares after opening at $4.44 on last trade day and at the end of the day closed at $4.02. Company price to cash ratio in past twelve months was calculated as 21.42. MannKind Corporation (NASDAQ:MNKD) showed a negative weekly performance of -31.98%.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) says PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR).Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares fell -71.60% in last trading session and ended the day on $2.80. PRAN return on equity ratio is recorded as -143.60% and its return on assets is -113.60%. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) yearly performance is 23.35%.
TheStreet Quant Ratings rates Exelixis, Inc. (NASDAQ:EXEL) as a sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Exelixis, Inc. (NASDAQ:EXEL) shares moved up 4.73% in last trading session and was closed at $3.54, while trading in range of $3.43 – $3.65. Exelixis, Inc. (NASDAQ:EXEL) year to date (YTD) performance is -42.25%.
On March 3, Pharmacyclics (NASDAQ:PCYC) Director Den Broek Richard Van sold 78,835 shares of the stock on the open market in a transaction dated Thursday, February 27th. The shares were sold at an average price of $146.63, for a total value of $11,559,576.05. Pharmacyclics, Inc. (NASDAQ:PCYC) weekly performance is -11.98%. On last trading day company shares ended up $100.22. Pharmacyclics, Inc. (NASDAQ:PCYC) distance from 50-day simple moving average (SMA50) is -23.99%. Analysts mean target price for the company is $167.40.